Curated Wealth Partners LLC Sells 316,167 Shares of HealthEquity, Inc. $HQY

Key Points

• Curated Wealth Partners cut its HealthEquity stake by 99.1%, selling 316,167 shares and retaining 2,908 shares valued at approximately $257,000.
• Analyst sentiment remains positive, with an overall “Moderate Buy” rating and an average price target of $112.20; Deutsche Bank recently raised its target to $142.
• HealthEquity reported quarterly earnings of $1.24 per share, ahead of the $1.19 estimate, while revenue rose 95.5% year over year to $350.73 million.

Curated Wealth Partners LLC lessened its stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 99.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,908 shares of the company's stock after selling 316,167 shares during the quarter. Curated Wealth Partners LLC's holdings in HealthEquity were worth $257,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Avior Wealth Management LLC purchased a new stake in shares of HealthEquity in the 3rd quarter valued at approximately $207,000. GAMMA Investing LLC lifted its stake in HealthEquity by 12.0% during the third quarter. GAMMA Investing LLC now owns 1,479 shares of the company's stock worth $131,000 after purchasing an additional 158 shares in the last quarter. Cim Investment Management Inc. boosted its position in shares of HealthEquity by 5.0% during the second quarter. Cim Investment Management Inc. now owns 4,007 shares of the company's stock worth $362,000 after buying an additional 191 shares during the period. Tidal Investments LLC boosted its position in shares of HealthEquity by 10.4% during the second quarter. Tidal Investments LLC now owns 42,235 shares of the company's stock worth $3,815,000 after buying an additional 3,988 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in shares of HealthEquity in the second quarter valued at $4,637,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on HQY shares. BTIG Research reissued a "buy" rating and set a $115.00 target price on shares of HealthEquity in a research note on Friday, August 28th. Weiss Ratings raised HealthEquity from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Friday. Wall Street Zen raised HealthEquity from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. Raymond James Financial reaffirmed a "strong-buy" rating on shares of HealthEquity in a research report on Thursday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of HealthEquity from $135.00 to $142.00 and gave the company a "buy" rating in a research report on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $112.20.

HealthEquity Stock Performance

Shares of HQY opened at $92.03 on Monday. The company has a 50-day simple moving average of $96.08 and a 200-day simple moving average of $91.47. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $7.61 billion, a PE ratio of 33.22, a P/E/G ratio of 1.45 and a beta of 0.24. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $107.62.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its quarterly earnings data on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.19 by $0.05. The firm had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The business's quarterly revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Equities research analysts predict that HealthEquity, Inc. will post 3.93 earnings per share for the current fiscal year.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Adrian Dillon sold 7,632 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at approximately $6,527,140.95. The trade was a 10.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.60% of the company's stock.

About HealthEquity

HealthEquity, Inc NASDAQ: HQY provides technology-enabled services for consumer-directed health and benefits accounts. The company administers health savings accounts (HSAs) and offers related products such as flexible spending accounts, health reimbursement arrangements, commuter benefits and other employee benefit programs.

Its platform is designed to help employers, benefits advisors, health plans and individuals manage benefits, make healthcare payments, access account information and invest eligible HSA funds.

Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.